How should I evaluate and treat an adult with Lambert‑Eaton myasthenic syndrome, including cancer screening and pharmacologic management?

Lambert-Eaton Myasthenic Syndrome: Evaluation and Treatment

Immediate Diagnostic Confirmation

Establish the diagnosis through the triad of clinical features, electromyography showing incremental response to repetitive stimulation, and detection of anti-voltage-gated calcium channel (VGCC) antibodies, which are present in >90% of LEMS patients and are highly specific for this diagnosis. 1, 2

Key Clinical Features to Identify

• Proximal muscle weakness predominantly affecting hip and shoulder muscles 3
• Reduced or absent muscle stretch reflexes 3
• Dry mouth (autonomic dysfunction) 3
• Post-exercise facilitation of strength (distinguishes from myasthenia gravis) 2
• Ocular and oropharyngeal muscles may be affected to a lesser extent 3

Electrophysiological Testing

• Low-amplitude compound muscle action potentials at rest 4, 3
• Dramatic increase (>100%) in amplitude after brief maximal voluntary contraction or high-frequency repetitive nerve stimulation 3, 2

Serological Confirmation

• Anti-VGCC antibodies (specifically P/Q-type) are present in >90% of cases 1, 2
• These antibodies are pathogenic and directly cause disease by impairing acetylcholine release at the neuromuscular junction 1

Mandatory Cancer Screening

Immediately initiate rigorous oncological screening upon LEMS diagnosis, as 50-60% of cases are paraneoplastic, most commonly associated with small cell lung cancer (SCLC). 3, 2, 5

Cancer Screening Protocol

• CT chest with contrast to detect SCLC 2, 5
• Whole-body PET-CT if initial CT is negative in high-risk patients (older age, smoking history) 2
• Repeat screening every 3-6 months for at least 2 years if initial workup is negative, as tumors may be occult at presentation 2
• Older patients with smoking history have highest risk for SCLC-LEMS 3
• Younger, non-smoking patients more likely have non-tumor LEMS (NT-LEMS) associated with autoimmune disease 3

First-Line Pharmacologic Treatment

Initiate 3,4-diaminopyridine (3,4-DAP) as first-line symptomatic therapy, as >85% of patients achieve clinically significant benefit, with marked improvement in over half. 1, 3

3,4-DAP Mechanism and Efficacy

• Potassium channel blocker that enhances neurotransmitter release at the neuromuscular junction 2
• Meta-analysis demonstrates significant improvement in compound muscle action potential amplitude (weighted mean difference 1.80 mV, 95% CI 0.82-2.78) 4
• Significant improvement in muscle strength scores in randomized controlled trials 4
• Long-term safety profile is favorable with sustained functional improvement 6

Common Adverse Effects to Monitor

• Paresthesias, gastrointestinal symptoms, and sleep disturbances are most common 6
• No new safety signals identified in long-term registry data 6

Immunotherapy for Inadequate Response

For patients with inadequate response to 3,4-DAP or more severe disease, add intravenous immunoglobulin (IVIg) at 2 g/kg over 5 days, which stabilizes neurologic symptoms with benefits lasting up to 8 weeks. 1, 7, 4

IVIg Administration

• Most effective when administered within 1 month of symptom onset 1, 7
• Significant improvement in myometric limb strength demonstrated in randomized controlled trials 4
• Clinical benefits can last up to 8 weeks, requiring repeated courses 7, 4

Alternative Immunotherapies

• Plasma exchange produces clear clinical benefit and can be considered 1, 3
• For non-paraneoplastic LEMS requiring long-term control, use prednisolone combined with azathioprine 7
• Second-line options include cyclophosphamide, mycophenolate, or rituximab if no improvement after initial immunotherapy 7, 8

Paraneoplastic LEMS Management

For SCLC-associated LEMS, tumor therapy is the essential first priority, as response to cancer therapy favorably affects the course of LEMS and successful tumor treatment often improves paraneoplastic symptoms. 1, 7, 8

Treatment Sequencing

• Oncologic treatment takes priority over immunotherapy 1, 5
• Concomitant immunotherapy does not adversely affect malignancy outcomes 7, 8
• Combined immunosuppressive therapy may temporarily stabilize symptoms but does not improve long-term outcomes 7, 8
• Prognosis in SCLC-LEMS is determined by tumor progression 2

Medications to Avoid

Avoid medications that worsen neuromuscular transmission: β-blockers, intravenous magnesium, fluoroquinolones, aminoglycosides, and macrolides. 7

Prognosis Expectations

• NT-LEMS does not reduce life expectancy 2
• SCLC-LEMS prognosis is determined by tumor progression, with death typically from cancer rather than neurologic complications 2
• Some neurologic deficits may be permanent due to low regenerative capacity of the nervous system 8
• Permanent sequelae should not be interpreted as treatment failure 8